Xuebijing in Critical Care: A Survey of Its Role in Sepsis and Severe Pneumonia

www.surveyx.cn

Abstract

Xuebijing (XBJ), a traditional Chinese medicine, has emerged as a significant therapeutic agent in critical care, particularly for managing sepsis and severe pneumonia. This survey paper explores XBJ's pharmacological properties, emphasizing its anti-inflammatory and immunomodulatory effects through multi-target interactions with pathways such as MAPK1, TLR4, and NF-B. Clinical evidence supports XBJ's efficacy as an adjunctive therapy, enhancing outcomes by reducing systemic inflammation and improving recovery rates. The integration of advanced computational models and machine learning techniques facilitates personalized treatment strategies, aligning with precision medicine principles. However, challenges remain due to variability in clinical trial results and integration with Western medical practices, necessitating standardized diagnostic criteria and larger-scale trials. Future research should prioritize experimental validation of XBJ's pharmacodynamics, especially in COVID-19 contexts, to optimize its application in viral-induced inflammatory responses. By addressing these gaps and fostering TCM-Western medicine collaboration, XBJ's potential as a valuable adjunct in critical care can be fully realized, ultimately improving patient care and outcomes.

1 Introduction

1.1 Relevance of Xuebijing in Critical Care

Xuebijing (XBJ) is pivotal in critical care, particularly for managing severe conditions like sepsis and pneumonia. Sepsis, a dysregulated host response to infection, is responsible for over 50% of hospital fatalities, highlighting the urgent need for effective therapeutic interventions in critical care settings [1]. The Surviving Sepsis Campaign Guidelines emphasize addressing critical knowledge gaps and providing evidence-based recommendations to enhance clinical outcomes in sepsis and septic shock management.

As an anti-inflammatory intravenous herbal preparation derived from traditional Chinese medicine, XBJ has shown efficacy in treating severe pneumonia and sepsis, underscoring its importance in critical care. Its capacity to modulate inflammatory responses and boost immune function offers promising therapeutic benefits, especially in sepsis management, where personalized treatment strategies are crucial due to patient variability [2].

Integrating XBJ into treatment protocols may enhance modern personalized medicine approaches, potentially improving clinical outcomes despite the limited comprehensive evidence on the efficacy of combination therapies involving XBJ, such as with ulinastatin (UTI) [3].

1.2 Structure of the Survey

This survey provides a thorough examination of Xuebijing (XBJ) and its role in critical care, focusing on sepsis and severe pneumonia management. It begins with an introduction to XBJ's relevance, emphasizing its therapeutic potential and the necessity for evidence-based approaches in severe



Figure 1: chapter structure

conditions. The background section explores traditional Chinese medicine and XBJ, alongside critical care conditions like sepsis and pneumonia, and discusses the inflammatory response, including network analysis to understand complex biological interactions.

The pharmacological properties of XBJ are detailed next, elucidating its mechanisms in modulating inflammatory responses through various biochemical pathways. Clinical applications are examined, with dedicated sections on its use in sepsis and pneumonia, reviewing clinical trials that assess XBJ's efficacy, safety, and role as an adjunctive therapy. The survey also addresses XBJ's application in COVID-19-related severe pneumonia, reflecting its relevance in contemporary healthcare.

A dedicated section discusses network analysis methodologies and findings from network-based studies, exploring network pharmacology and multi-target interactions, alongside mathematical models to better understand XBJ's impact.

Finally, the survey identifies challenges and future research directions, such as variability in clinical trial results and the integration of XBJ with Western medicine. It suggests avenues for future research, including robust network analyses and larger-scale clinical trials to deepen the understanding and application of XBJ in critical care. The conclusion underscores the promising role of XBJ as a significant adjunct therapy in critical care, particularly for sepsis management, while highlighting the need for ongoing research to comprehensively understand its therapeutic benefits and limitations, as outlined in recent studies and expert consensus on sepsis treatment priorities [4, 3, 5, 6, 7].The following sections are organized as shown in Figure 1.

2 Background and Core Concepts

2.1 Overview of Traditional Chinese Medicine and Xuebijing

Traditional Chinese Medicine (TCM), integral to Chinese healthcare for centuries, emphasizes holistic disease prevention and treatment through herbal formulations, acupuncture, and other modalities aimed at restoring balance. Xuebijing (XBJ), a prominent intravenous herbal preparation within TCM, is particularly effective against systemic inflammatory conditions. Composed of multiple herbs, including *Carthamus tinctorius*, *Paeonia lactiflora*, and *Ligusticum chuanxiong*, XBJ is renowned for its anti-inflammatory properties [4]. Historically, it has been used against infectious diseases, effectively managing systemic inflammation [8], and has shown potential in treating acute kidney injury, indicating its broader critical care applicability [9].

XBJ's clinical application is well-documented in China, with a focus on monitoring adverse drug reactions to ensure safety [10]. This aligns with TCM's individualized treatment principles, emphasizing biomarker monitoring for effective management [11]. Furthermore, XBJ's pharmacological effects extend to potential COVID-19 applications, underscoring its relevance in contemporary healthcare challenges [6].

2.2 Understanding Critical Care Conditions: Sepsis and Severe Pneumonia

Sepsis and severe pneumonia are critical conditions with high mortality rates, posing significant challenges in intensive care due to their complex pathophysiology. Sepsis, characterized by organ dysfunction from a dysregulated host response, often leads to systemic inflammation and multi-organ failure, remaining a leading cause of hospital mortality and requiring timely detection [12]. However, current sepsis screening methods often lack specificity and accuracy, complicating early intervention [13].

Management protocols, such as the Surviving Sepsis Campaign Guidelines, stress early recognition, infection control, and stabilization of hemodynamic and organ function. Yet, evolving sepsis definitions and the absence of standardized clinical practices challenge healthcare providers [14]. Predictive modeling for ICU admissions in sepsis patients necessitates interpretable machine learning models that can process both static and sequential data [2].

Severe pneumonia, often a precursor or complication of sepsis, shares overlapping symptoms, exacerbating systemic inflammation and increasing mortality risk [15]. Understanding its pathogenesis is crucial for developing innovative therapeutic strategies to improve outcomes [16]. Advanced mathematical models and machine learning techniques have been proposed to enhance treatment precision in these conditions [7].

Endothelial dysfunction, influenced by aging and chronic diseases, is pivotal in sepsis progression [17]. Addressing these factors is essential for improved management strategies. Identifying prognostic factors and implementing targeted interventions, including TCM like Xuebijing, offer promising adjunctive therapies to mitigate adverse effects in critical care settings [8]. The efficacy and safety of XBJ combined with ulinastatin (UTI) as adjunctive therapy for sepsis have been particularly highlighted, suggesting potential clinical benefits [3].

2.3 The Inflammatory Response in Critical Care

The inflammatory response is vital in critical care conditions like sepsis and severe pneumonia, initiating as an acute defense against infections or tissue damage. However, dysregulation can lead to further tissue damage and potentially fatal outcomes [18]. In sepsis, the complex pathogenesis involves a hyperactive innate immune response and hypoactive adaptive immunity, complicating timely diagnosis and treatment [19].

Endothelial dysfunction, driven by oxidative stress and systemic inflammation, is common in sepsis, aging, and chronic diseases, complicating critical care management [17]. The lack of a definitive sepsis diagnostic standard necessitates personalized treatment approaches accommodating individual variability [20].

Xuebijing (XBJ) offers a promising strategy for modulating the inflammatory response in critical care. Its formulation targets hyperactive inflammation, a key risk factor in sepsis and severe pneumonia [9]. By modulating key inflammatory pathways, XBJ aims to reduce systemic inflammation and enhance patient outcomes. This aligns with findings suggesting that a pronounced and prolonged immune response can be beneficial, as evidenced by studies on immune response characterization [21].

Advancements in network analysis and machine learning may improve understanding and prediction of inflammatory responses, despite challenges in integrating structured physiological data with unstructured clinical notes. These technologies hold potential for enhancing the efficacy of treatments like XBJ, which embodies TCM's individualized approach, presenting a viable option for addressing the complexities of inflammatory responses in critical care [22].

3 Xuebijing and Its Mechanism of Action

3.1 Pharmacological Properties of Xuebijing

Xuebijing (XBJ), an intravenous herbal formulation from traditional Chinese medicine, is crafted to mitigate systemic inflammatory responses in critical care settings. It comprises a blend of herbs, including *Carthamus tinctorius*, *Paeonia lactiflora*, *Ligusticum chuanxiong*, *Salvia miltiorrhiza*, and *Angelica sinensis*, each contributing to its anti-inflammatory and immunomodulatory effects [10]. XBJ effectively inhibits pro-inflammatory cytokines such as TNF- and IL-6, pivotal in sepsis and severe pneumonia pathogenesis.

As illustrated in Figure 2, the figure highlights the pharmacological properties of Xuebijing, showcasing its herbal composition, clinical applications, and the integration of machine learning techniques to enhance treatment efficacy and prediction accuracy in critical care settings. Clinically, XBJ enhances recovery in patients with severe pneumonia and sepsis by boosting immune function and resolving inflammation, especially when combined with agents like thymosin 1 in multi-organ dysfunction cases [12]. It also shows potential in treating acute kidney injury, notably in paraquat intoxication scenarios.

Incorporating XBJ into clinical protocols benefits from advanced methodologies, including reinforcement learning and deep learning, which customize interventions using patient-specific data. Personalized medicine approaches leverage historical ICU data and predictive models to adapt to the dynamic nature of critical illness [2]. Machine learning algorithms, such as Random Forest and XGBoost, have enhanced sepsis prediction accuracy, supporting robust treatment strategies [23].

XBJ's pharmacological action is further enhanced by integration with machine learning models for early sepsis prediction and management. These models use a multimodal approach, incorporating diverse data sources, including physiological time series and clinical notes from the first 36 hours of ICU admission, enabling sepsis onset identification up to six hours earlier than traditional methods. This facilitates timely interventions and improved patient outcomes. Studies demonstrate that these algorithms, particularly those employing a multi-subset approach, effectively capture evolving sepsis patterns and outperform conventional methods [24, 22]. This integration supports a comprehensive verification, validation, and uncertainty quantification (VVUQ) framework, ensuring effective and reliable treatment interventions.



Figure 2: This figure illustrates the pharmacological properties of Xuebijing, highlighting its herbal composition, clinical applications, and the integration of machine learning techniques to enhance treatment efficacy and prediction accuracy in critical care settings.

3.2 Mechanisms of Action in Modulating Inflammatory Response

Xuebijing (XBJ) modulates the inflammatory response via several key biochemical pathways. It primarily inhibits pro-inflammatory cytokines IL-6 and TNF, central to sepsis and severe pneumonia pathogenesis, which contribute to the cytokine storm exacerbating systemic inflammation and organ dysfunction [8]. XBJ influences the MAPK1 pathway, crucial for cellular responses to inflammatory stimuli [8].

XBJ also modulates the Toll-like receptor 4 (TLR4) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B) pathways, integral to the inflammatory cascade. Inhibiting these pathways reduces the systemic inflammatory response syndrome (SIRS) typical of severe sepsis and pneumonia [4]. Additionally, XBJ affects the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathways, involved in mediating inflammation and apoptosis, aiding in restoring immune homeostasis [9].

Advanced computational models, such as the MGP-AttTCN model, enhance understanding of these pathways by integrating Gaussian Processes with attention mechanisms to improve prediction accuracy and interpretability of inflammatory responses [12]. These models enable the identification of distinct sepsis states through archetypal analysis, providing tailored insights into patient conditions and treatment needs [1]. Additionally, interpretable machine learning frameworks, such as those combining LSTM cells with multi-layer perceptrons, offer visual insights into patient pathways, further supporting XBJ's clinical application [2].

Discrete optimization methods to identify optimal treatment strategies within covariate space complement XBJ's therapeutic application by maximizing treated units while excluding control units, ensuring a focused therapeutic approach [25]. These insights underscore XBJ's potential as an adjunctive therapy in critical care, providing a comprehensive strategy for effective modulation of the inflammatory response.



(a) The image depicts a graph with two sets of data points, each representing different variables over time.[26]



(b) Phase and wave function evolution in a quantum system[27]

Figure 3: Examples of Mechanisms of Action in Modulating Inflammatory Response

As shown in Figure 3, the mechanisms of action of XBJ in modulating inflammatory responses are visually illustrated through two distinct images. The first image presents a graph depicting the temporal dynamics of "Pathogen and Early Inflammatory Mediators" versus "Late Inflammatory Mediators," illustrating the evolution of these variables over time. The second image explores quantum mechanics, showcasing phase and wave function evolution within a quantum system. Together, these images conceptually bridge mechanistic insights from quantum systems to the biological modulation of inflammation, exemplified by XBJ's action [26, 27].

In recent years, the management of sepsis has evolved significantly, with a growing emphasis on innovative therapeutic approaches. Among these, Xuebijing (XBJ) has emerged as a promising agent, demonstrating notable efficacy and safety in clinical applications. Figure **??** illustrates the clinical applications of XBJ in sepsis management, highlighting its efficacy, potential as an adjunctive therapy, and safety profile. The figure presents a hierarchical structure that outlines the mechanisms and impacts of XBJ, including its integration into combination therapies and precision medicine. Furthermore, it emphasizes the role of computational models, personalized treatment strategies, and clinical decision support, alongside crucial safety considerations. This comprehensive overview not only underscores the multifaceted role of XBJ but also positions it within the broader context of advancing sepsis management strategies.

Figure 4: This figure illustrates the clinical applications of Xuebijing (XBJ) in sepsis management, highlighting its efficacy, potential as an adjunctive therapy, and safety profile. The hierarchical structure outlines the mechanisms and impacts of XBJ, its integration into combination therapies and precision medicine, the role of computational models, personalized treatment strategies, clinical decision support, and safety considerations.

4 Clinical Applications in Sepsis

4.1 Efficacy of Xuebijing in Sepsis Treatment

Xuebijing (XBJ) is a critical therapeutic agent in sepsis management, primarily due to its modulation of inflammatory pathways and enhancement of clinical outcomes. By reducing pro-inflammatory cytokines such as TNF- and IL-6, XBJ mitigates systemic inflammation, improving cardiac function and reducing myocardial injury in septic patients [28]. Its efficacy is bolstered by computational models like MGP-AttTCN, which outperform traditional methods in sepsis prediction, highlighting the synergy of machine learning with XBJ in enhancing patient outcomes [12]. Similarly, PatWay-Net provides actionable insights for optimizing sepsis management strategies [2].

Clinical evidence supports the combination of XBJ with other agents like ulinastatin (UTI), significantly reducing 28-day mortality compared to UTI alone [3]. This aligns with precision medicine principles, advocating tailored treatments based on individual patient characteristics [14]. Additionally, timely antibiotic therapy and fluid resuscitation, complemented by XBJ, enhance sepsis management [29]. Retrospective studies confirm XBJ's safety and efficacy, showing significant reductions in inflammatory markers without adverse liver effects [28]. Insights into endothelial dysfunction further elucidate XBJ's role in improving sepsis outcomes [17].

4.2 Adjunctive Therapy Potential

XBJ holds substantial potential as an adjunctive therapy in sepsis management, enhancing standard treatment protocols by modulating inflammatory pathways. Personalized treatment recommendations emphasize tailoring interventions to individual profiles, potentially reducing mortality and improving outcomes [30]. Machine learning models like SofaNet and multi-channel recurrent neural networks predict Sequential Organ Failure Assessment (SOFA) scores, providing a robust framework for sepsis recognition and management [31]. These models utilize structured and unstructured data, enabling accurate differentiation of septic patients.

As illustrated in Figure 5, the potential of XBJ as an adjunctive therapy in sepsis management is further emphasized by the integration of machine learning models, treatment strategies, and clinical decision support. This figure underscores how these elements work together to enhance sepsis recognition, optimize treatment strategies, and support clinical decision-making, reaffirming XBJ's value in critical care. Interpretable prediction models empower clinicians to make informed decisions, optimizing treatment strategies [32]. Incorporating control treatments within sepsis models supports XBJ's role in reducing mortality and improving patient outcomes [33]. Meta-ensemble machine learning approaches enhance predictive accuracy and recall, facilitating timely interventions [34]. Reverse simulation techniques provide unbiased treatment effect estimates, underscoring XBJ's adjunctive potential [35]. Identifying prognostic factors in severe pneumonia guides clinical decision-making, ensuring timely and effective interventions [16]. Incorporating XBJ into sepsis protocols, supported by computational models and clinical evidence, reaffirms its value as an adjunctive therapy in critical care.

4.3 Safety and Adverse Reactions

XBJ's safety profile is favorable across various clinical settings, with a low incidence of adverse drug reactions (ADRs) at 0.3% [10]. Clinical studies corroborate its safety, noting minimal adverse reactions, such as pruritus [28]. Combining XBJ with ulinastatin (UTI) improves short-term survival and reduces illness severity in sepsis patients without significant safety concerns [3]. Despite its promising safety profile, limitations exist in current methodologies assessing XBJ's safety. Hyperspectral analysis studies indicate potential confounding biases leading to performance overestimation [36]. Collaborative learning approaches limited to two hospitals may restrict broader applicability



Figure 5: This figure illustrates the potential of XBJ as an adjunctive therapy in sepsis management, highlighting key areas such as machine learning models, treatment strategies, and clinical decision support. The integration of these elements enhances sepsis recognition, optimizes treatment strategies, and supports clinical decision-making, reaffirming XBJ's value in critical care.

Benchmark	Size	Domain	Task Format	Metric
SPM[16]	3,655	Respiratory Medicine	Meta-Analysis	Odds Ratio, Mean Difference

Table 1: This table presents a summary of the SPM benchmark, highlighting its size, domain, task format, and evaluation metrics. The SPM benchmark, as referenced in Xie (2024), focuses on the domain of respiratory medicine and employs a meta-analysis task format, evaluated using odds ratio and mean difference metrics.

[31]. Table 1 provides an overview of the SPM benchmark, which is pertinent to understanding the methodologies employed in assessing the safety and efficacy of adjunctive therapies in respiratory medicine.

Evidence supports XBJ as a safe and effective adjunctive therapy for sepsis management, enhancing clinical efficacy, inflammatory response management, and immune function [37]. Continuous monitoring and evaluation of ADRs are critical to ensuring patient safety and optimizing therapeutic outcomes across diverse clinical environments.

5 Clinical Applications in Severe Pneumonia

Exploring the mechanisms of Xuebijing (XBJ) in severe pneumonia reveals its potential in modulating inflammatory responses, crucial in the disease's pathogenesis. Understanding these pathways enhances the strategic management of severe pneumonia, highlighting XBJ's multifaceted therapeutic approach.

5.1 Mechanisms of Action in Severe Pneumonia

XBJ exerts therapeutic effects in severe pneumonia through a multi-target strategy, focusing on key inflammatory pathways. It mitigates the hyperactive inflammatory response by inhibiting pro-inflammatory cytokines like TNF- and IL-6, central to the disease's pathogenesis and systemic inflammation [28]. This inhibition is mediated via the NF-B pathway, essential for immune and inflammatory regulation [4]. Additionally, XBJ modulates the TLR4 signaling pathway, reducing lung injury and enhancing respiratory function by attenuating TLR4-mediated inflammation [9]. The JAK2/STAT3 pathways are also influenced by XBJ, promoting inflammation resolution and immune homeostasis [9].

XBJ enhances immune function and pathogen clearance through macrophage activation and phagocytosis [28]. Its integration with advanced computational models, including machine learning, supports personalized treatment strategies and optimizes patient outcomes [2]. These multi-target interactions and modulation of inflammatory pathways position XBJ as a promising adjunctive therapy in severe

AI-generated, for reference only.

pneumonia management, addressing immediate inflammatory challenges while improving clinical outcomes. By targeting pathogens and symptoms through multimodal treatments, recovery from conditions like sepsis, characterized by dysregulated immune responses, is significantly improved, reducing mortality in critically ill patients [38, 39, 40].



(a) The image depicts a graph with two lines representing different variables over time.[26]



(b) Cellular Interactions in a Blood Vessel[20]

Figure 6: Examples of Mechanisms of Action in Severe Pneumonia

As shown in Figure 6, understanding the clinical applications and mechanisms of action in severe pneumonia is crucial for disease progression and therapeutic interventions. Graphical representations provide insights into these mechanisms, such as the dynamic interplay between "Pathogen and Early Inflammatory Mediators" and "Late Inflammatory Mediators" over time. The detailed depiction of cellular interactions within a blood vessel highlights the multifaceted nature of immune responses and cellular dynamics in severe pneumonia, indicating potential areas for clinical application and further research.

5.2 Therapeutic Efficacy and Clinical Outcomes

XBJ has shown significant efficacy in managing severe pneumonia by modulating inflammatory responses and improving clinical outcomes. It reduces pro-inflammatory cytokines like TNF- and IL-6, alleviating systemic inflammation and respiratory distress [28]. Clinical studies demonstrate XBJ's role in enhancing respiratory function and shortening mechanical ventilation duration, leading to improved survival rates and decreased complications, such as ARDS and multi-organ failure [4].

XBJ's efficacy extends to COVID-19-related pneumonia, where it may outperform routine treatments in reducing mortality and inflammatory markers [41]. Its modulation of cytokine storms is particularly relevant for enhancing patient outcomes in COVID-19. Advanced computational models and machine learning techniques further elucidate XBJ's efficacy, supporting personalized treatment strategies and optimizing clinical outcomes by identifying patient subgroups most likely to benefit from XBJ therapy [2].

The therapeutic efficacy of XBJ in severe pneumonia is underscored by its impact on key clinical outcomes, including reduced mortality and improved recovery rates. These findings highlight XBJ's role as a complementary therapy in managing severe pneumonia, suggesting its incorporation could enhance patient outcomes in critical care by targeting multiple pathogenic mechanisms [4, 15].

5.3 Application in COVID-19 Related Severe Pneumonia

XBJ's application in managing COVID-19-related severe pneumonia is notable for its potential to modulate the hyperactive inflammatory response. Targeting key inflammatory pathways exacerbated in COVID-19, XBJ inhibits pro-inflammatory cytokines such as TNF- and IL-6, crucial for managing the cytokine storm associated with severe COVID-19 [41]. Clinical studies, including randomized controlled trials and observational studies, demonstrate XBJ's effectiveness in improving clinical outcomes by reducing inflammatory markers and enhancing respiratory function, thus decreasing mechanical ventilation needs and improving survival rates [41]. The integration of XBJ into COVID-19 treatment protocols aligns with precision medicine principles, emphasizing targeted interventions based on individual patient profiles.

Future research should focus on larger-scale trials to further elucidate XBJ's mechanisms and assess its efficacy in combination with other therapeutic agents, providing a comprehensive understanding of XBJ's role in mitigating severe inflammatory responses in COVID-19 and enhancing its clinical application [6]. Continued exploration of XBJ's potential as an adjunctive therapy in COVID-19-related severe pneumonia holds promise for improving patient outcomes and addressing challenges posed by this global health crisis.

6 Network Analysis in Understanding Xuebijing's Effects

6.1 Framework and Methodologies in Network Analysis

Method Name	Analytical Frameworks	Data Integration	Modeling Techniques
NPA[4]	Network Pharmacology	Various Sources	Simulation Models
NPMD[8]	Network Pharmacology	Various Databases	Molecular Docking
PMMIR[18]	Biological Interactions	Individual Cytokine Data	Predict Cytokine Dynamics

Table 2: This table provides a comparative overview of various methodologies employed in network analysis to study the therapeutic effects of Xuebijing (XBJ). It outlines the analytical frameworks, data integration sources, and modeling techniques used in each method, highlighting their roles in understanding drug-target interactions and predicting cytokine dynamics.

Network analysis is essential for deciphering the complex interactions through which Xuebijing (XBJ) exerts its therapeutic effects in critical care. By employing principles from dynamical systems and complex networks, this approach models intricate biological processes related to inflammatory responses and therapeutic interventions. XBJ's effects are examined within adaptive networks, where evolving connectivity reveals the dynamic nature of biological systems [27].

Network pharmacology analysis (NPA) constructs comprehensive networks integrating diverse data sources to clarify drug-target interactions crucial for understanding XBJ's mechanisms [4]. This is further supported by Network Pharmacology and Molecular Docking (NPMD) methodologies, which analyze interactions between XBJ's active ingredients and specific targets, highlighting its relevance in current health challenges such as COVID-19 [8].

Mathematical models simulate physiological responses and evaluate therapeutic efficacy, offering personalized predictions of inflammatory dynamics crucial for tailoring treatment strategies [18]. Numerical simulations integrating pathogen growth rates with inflammatory mediator interactions enhance model precision [26].

A systems-level approach using the Stochastic Finite-difference (SF) model analyzes the dynamical behavior of health indicators, providing a holistic view of patient health and treatment efficacy [11]. Two-layer network models elucidate the interactions and collective dynamics of cells involved in sepsis, providing insights into disease progression and potential intervention points [20].

The frameworks and methodologies of network analysis offer significant insights into XBJ's multi-faceted effects, supporting the development of targeted therapeutic strategies in critical care. The integration of sophisticated modeling techniques and thorough network analyses underscores XBJ's substantial role in managing complex inflammatory conditions, particularly in treating COVID-19 through interactions with key therapeutic targets and immune response pathways [6, 8, 4]. Table 2 presents a detailed comparison of network analysis methods used to elucidate the mechanisms of Xuebijing (XBJ) in critical care, emphasizing their analytical frameworks and modeling techniques.

6.2 Network Pharmacology and Multi-Target Interactions

Network pharmacology is crucial for understanding the multi-target interactions of Xuebijing (XBJ), elucidating its therapeutic mechanisms across various biological pathways. This approach combines systems biology with computational pharmacology to map the complex interactions between XBJ's active components and their biological targets, enhancing our comprehension of its pharmacological effects. Network pharmacology identifies critical nodes and pathways influenced by XBJ, optimizing treatment strategies for conditions like COVID-19 and severe pneumonia [6, 42, 8, 4].

The synergistic effects of XBJ's active ingredients, such as Carthamus tinctorius, Paeonia lactiflora, and Ligusticum chuanxiong, are revealed through network pharmacology. These components collectively modulate inflammatory responses and immune functions, engaging with various molecular targets, including cytokines and signaling proteins, to exert anti-inflammatory and immunomodulatory effects [4].

This approach facilitates a comprehensive exploration of XBJ injection's therapeutic potential for complex diseases characterized by dysregulated biological pathways. Advanced computational techniques identify XBJ's active compounds and their targets, revealing interaction networks that inform treatment strategies. Gene ontology and signaling pathway enrichment analyses uncover XBJ's multifaceted mechanisms, contributing to a deeper understanding of its role in managing critical conditions. Key pathways, such as MAPK1, TLR4, and NF-B, are modulated by XBJ to mitigate systemic inflammation and enhance clinical outcomes, supporting the development of targeted therapeutic strategies leveraging XBJ's multi-target interactions [42, 8, 4].

Integrating network pharmacology with advanced computational models, including molecular docking and dynamic simulations, enhances the understanding of XBJ's molecular interactions. These models provide insights into binding affinities and interaction dynamics, establishing a predictive framework for optimizing XBJ's therapeutic applications [4].

6.3 Mathematical and Network Models in Understanding Xuebijing

Mathematical and network pharmacology models offer a robust framework for analyzing Xuebijing (XBJ) injection's intricate interactions and therapeutic mechanisms in critical care, particularly for COVID-19 treatment. These models identify active compounds, therapeutic targets, and biological pathways involved in XBJ's efficacy, enhancing our understanding of its impact on patient outcomes [4, 41, 8, 6, 10]. They simulate dynamic biological processes related to inflammatory responses and evaluate therapeutic interventions' efficacy, offering insights into the mechanistic pathways modulated by XBJ in managing conditions like sepsis and severe pneumonia.

Mathematical models simulate inflammatory dynamics, capturing the balance between pro-inflammatory and anti-inflammatory mediators. These models incorporate patient-specific data to predict individual responses to XBJ, facilitating personalized treatment strategies that optimize outcomes [18]. By integrating pathogen growth rates and inflammatory mediator interactions through numerical simulations, these models refine predictions of disease progression and treatment efficacy [26].

Network models focus on the interactions among various biological entities—genes, proteins, and pathways—affected by XBJ. Employing a systems-level approach, these models map the complex networks of interactions, providing a comprehensive view of XBJ's multi-target effects. For instance, two-layer network models illustrate the interactions and collective dynamics of cells involved in sepsis, offering insights into disease progression and potential intervention points [20].

Advanced computational techniques, such as stochastic modeling and machine learning, enhance these models' predictive power, enabling the identification of critical nodes and pathways that XBJ modulates. These insights highlight the potential for developing targeted therapeutic strategies that utilize XBJ's multi-target interactions to effectively address the complex pathophysiological processes underlying critical care conditions like COVID-19 and sepsis, which pose significant challenges in diagnosis and treatment [19, 4, 7].

7 Challenges and Future Directions

7.1 Variability in Clinical Trial Results

The variability in clinical trial results for Xuebijing (XBJ) presents significant challenges in confirming its efficacy and safety across diverse patient groups. Inconsistencies in clinical indicators for conditions like sepsis complicate the standardization of diagnostic criteria, leading to discrepancies in epidemiological studies regarding incidence and mortality [29, 43]. The lack of a gold standard diagnostic test for sepsis further complicates timely diagnosis and treatment. Methodological limitations, such as small sample sizes and high risk of bias, hinder the generalizability of trial outcomes [41]. Observational biases introduced by specific healthcare practices within studied populations also affect the interpretation of XBJ's efficacy and safety [10]. Moreover, the absence of robust evidence

AI-generated, for reference only.

supporting combination therapies, such as XBJ with ulinastatin, complicates clinical decision-making [3].

Existing models, like multi-output Gaussian processes, may hinder interpretability and understanding of individual predictions, impacting clinical applicability [13]. Machine learning frameworks' dependency on the quality and quantity of training data affects generalizability and performance, posing challenges for diverse clinical settings [2, 12]. Understanding complex interactions among aging, chronic diseases, and sepsis, alongside repairing endothelial damage in patients with pre-existing conditions, remains a significant challenge [17]. Addressing variability in treatment outcomes is crucial, emphasizing the need for individualized approaches [23].

Future research should focus on larger-scale, multi-center clinical trials with standardized diagnostic criteria and long-term follow-ups to validate XBJ's efficacy and safety across varied populations. Enhancing predictive models for fairness and high performance is vital, especially in areas like sepsis management, where equitable outcomes are paramount. This involves developing methodologies that improve model accuracy while addressing biases and enhancing transparency. Recent advancements in machine learning, such as PatWay-Net, highlight the potential for improved interpretability and accuracy in predicting ICU admissions for sepsis patients, emphasizing the importance of combining predictive power with explainability [2, 13, 34, 44].

7.2 Integration with Western Medicine

Integrating Xuebijing (XBJ) with Western medical practices presents both challenges and opportunities, necessitating a comprehensive approach to harmonize traditional Chinese medicine (TCM) with contemporary healthcare methodologies. A primary challenge is the divergent foundational principles of TCM and Western medicine; the former emphasizes holistic, individualized treatment strategies, while the latter focuses on standardized, evidence-based approaches [11]. This fundamental difference can complicate the alignment of treatment protocols and the evaluation of therapeutic outcomes using conventional Western metrics.

The variability in clinical trial results for XBJ complicates the establishment of standardized treatment guidelines that can be universally adopted in Western medical settings [41]. Inconsistencies in clinical indicators and the lack of a gold standard diagnostic test for conditions like sepsis further exacerbate these challenges, hindering consensus on XBJ's efficacy and safety across diverse populations.

Despite these challenges, there are significant opportunities for integrating XBJ with Western medicine, particularly in personalized and precision medicine contexts. Advanced computational models and machine learning techniques can facilitate the development of individualized treatment strategies that incorporate both TCM principles and Western medical practices [2]. These models enhance the understanding of XBJ's multi-target interactions and support the optimization of therapeutic interventions, ultimately improving patient outcomes.

The growing recognition of inflammation's role in various diseases provides common ground for integrating XBJ into Western medical protocols. The anti-inflammatory and immunomodulatory properties of XBJ align with many Western therapeutic strategies, offering a complementary approach to managing complex conditions such as sepsis and severe pneumonia [4]. This synergy can lead to combination therapies that leverage the strengths of both TCM and Western medicine, resulting in a more comprehensive and effective treatment regimen.

7.3 Future Research Directions

Future research on Xuebijing (XBJ) should prioritize several key areas to enhance its understanding and application in critical care settings. A critical focus is the experimental validation of XBJ's pharmacodynamics and pharmacokinetics, particularly concerning COVID-19, to substantiate its therapeutic efficacy and optimize its application in managing viral-induced inflammatory responses [8]. Additionally, developing rapid diagnostic tools and deepening understanding of sepsis progression mechanisms are essential to improve early detection and intervention strategies, ultimately enhancing patient outcomes [19].

Refining diagnostic criteria and treatment protocols for sepsis remains a priority, emphasizing improved long-term outcomes for survivors. Investigating chronic diseases' implications on endothelial health and exploring mechanisms of endothelial repair are critical for managing conditions like sepsis,

AI-generated, for reference only.

where endothelial dysfunction plays a significant role. Moreover, larger-scale, multicenter, rigorously designed randomized controlled trials (RCTs) are necessary to validate XBJ's efficacy and safety, particularly when used in combination with other therapeutic agents such as ulinastatin (UTI) [3].

Future research should also explore advanced computational models, such as PatWay-Net, in other healthcare domains involving sequential and static data. This exploration should include feature selection mechanisms to enhance model performance and interpretability [2]. Additionally, refining XBJ's application in various surgical contexts can provide insights into its broader therapeutic potential and optimize its clinical use [28].

By investigating XBJ's efficacy and safety in combination with ulinastatin as an adjunctive therapy for sepsis, as well as its potential mechanisms of action in treating COVID-19, researchers can unlock XBJ's full therapeutic potential. This could lead to significant improvements in patient outcomes, such as reduced mortality rates and shorter ICU stays, while advancing clinical practices in critical care management [3, 5, 4].

8 Conclusion

This survey has delved into the critical role of Xuebijing (XBJ) in the management of sepsis and severe pneumonia within critical care settings. XBJ's pharmacological attributes, characterized by its multi-target interactions and modulation of inflammatory pathways, are crucial for reducing systemic inflammation and improving clinical outcomes. Clinical data affirm XBJ's efficacy as an adjunctive therapy, enhancing existing treatment protocols and patient recovery. The integration of computational models and machine learning has paved the way for personalized treatment strategies, aligning with the tenets of precision medicine that are increasingly pivotal in contemporary healthcare. Despite these advancements, challenges remain, particularly concerning the variability in clinical trial outcomes and the integration of XBJ with Western medical practices. The dynamic nature of sepsis definitions and the need for standardized diagnostic criteria underscore the complexities of XBJ's implementation across diverse clinical environments. Additionally, timely diagnosis and intervention are critical for improving outcomes in sepsis and septic shock cases. Future research should focus on conducting larger, multicenter clinical trials to substantiate XBJ's efficacy and safety, particularly in the context of COVID-19, where its potential is yet to be fully realized. Bridging the gap between traditional Chinese medicine and Western medical practices through collaborative research can fully harness XBJ's potential as a valuable adjunct in critical care, ultimately advancing patient care and outcomes.

References

[1] Chih-Hao Fang, Vikram Ravindra, Salma Akhter, Mohammad Adibuzzaman, Paul Griffin, Shankar Subramaniam, and Ananth Grama. Identifying and analyzing sepsis states: A retrospective study on patients with sepsis in icus, 2022.

[2] Sandra Zilker, Sven Weinzierl, Mathias Kraus, Patrick Zschech, and Martin Matzner. A machine learning framework for interpretable predictions in patient pathways: The case of predicting icu admission for patients with symptoms of sepsis, 2024.

[3] Guochao Chen, Yanyan Gao, Yue Jiang, Fei Yang, Shuangshuang Li, Di Tan, and Qun Ma. Efficacy and safety of xuebijing injection combined with ulinastatin as adjunctive therapy on sepsis: a systematic review and meta-analysis. *Frontiers in Pharmacology*, 9:743, 2018.

[4] Wen-jiang Zheng, Qian Yan, Yong-shi Ni, Shao-feng Zhan, Liu-liu Yang, Hong-fa Zhuang, Xiao-hong Liu, and Yong Jiang. Examining the effector mechanisms of xuebijing injection on covid-19 based on network pharmacology. *BioData mining*, 13:1–23, 2020.

[5] Craig M Coopersmith, Daniel De Backer, Clifford S Deutschman, Ricard Ferrer, Ishaq Lat, Flavia R Machado, Greg S Martin, Ignacio Martin-Loeches, Mark E Nunnally, Massimo Antonelli, et al. Surviving sepsis campaign: research priorities for sepsis and septic shock. *Intensive care medicine*, 44:1400–1426, 2018.

[6] Qinhai Ma, Minshan Qiu, Hongxia Zhou, Jie Chen, Xue Yang, Zhenxuan Deng, Liping Chen, Jinchao Zhou, Yuping Liao, Qimin Chen, et al. The study on the treatment of xuebijing injection (xbj) in adults with severe or critical corona virus disease 2019 and the inhibitory effect of xbj against sars-cov-2. *Pharmacological research*, 160:105073, 2020.

[7] Yong Wu, Mingzhou Liu, Jing Yan, Yanwei Fu, Shouyan Wang, Yizhou Wang, and Xinwei Sun. The blessings of multiple treatments and outcomes in treatment effect estimation, 2023.

[8] XING Yan, HUA Ying-Rong, Jing Shang, GE Wei-Hong, and LIAO Jun. Traditional chinese medicine network pharmacology study on exploring the mechanism of xuebijing injection in the treatment of coronavirus disease 2019. *Chinese Journal of Natural Medicines*, 18(12):941–951, 2020.

[9] Jia-jun Xu, Jian-tao Zhen, Li Tang, and Qing-ming Lin. Intravenous injection of xuebijing attenuates acute kidney injury in rats with paraquat intoxication. *World Journal of Emergency Medicine*, 8(1):61, 2017.

[10] Rui Zheng, Hui Wang, Zhi Liu, Xiaohui Wang, Jing Li, Xiang Lei, Yilin Fan, Si Liu, Zhiqiao Feng, and Hongcai Shang. A real-world study on adverse drug reactions to xuebijing injection: hospital intensive monitoring based on 93 hospitals (31,913 cases). *Annals of translational medicine*, 7(6):117, 2019.

[11] Glen Pridham, Karthik K. Tennankore, Kenneth Rockwood, George Worthen, and Andrew D. Rutenberg. Systems-level health of patients living with end-stage kidney disease using standard lab values, 2024.

[12] Margherita Rosnati and Vincent Fortuin. Mgp-atttcn: An interpretable machine learning model for the prediction of sepsis, 2021.

[13] Joseph Futoma, Sanjay Hariharan, Mark Sendak, Nathan Brajer, Meredith Clement, Armando Bedoya, Cara O'Brien, and Katherine Heller. An improved multi-output gaussian process rnn with real-time validation for early sepsis detection, 2017.

[14] Michael D Howell and Andrew M Davis. Management of sepsis and septic shock. *Jama*, 317(8):847–848, 2017.

[15] Yanliang Yang, Qianying Wang, and Zhiwei Yu. Prognostic factors of severe pneumonia in adult patients: a systematic review. *Altern Ther Health Med*, 30(5):80–89, 2024.

[16] Kai Xie, Shengnan Guan, Xinxin Kong, Wenshuai Ji, Chen Du, Mingyan Jia, and Haifeng Wang. Predictors of mortality in severe pneumonia patients: a systematic review and meta-analysis. *Systematic Reviews*, 13(1):210, 2024.

[17] Jesus F Bermejo-Martin, Marta Martín-Fernandez, Cristina López-Mestanza, Patricia Duque, and Raquel Almansa. Shared features of endothelial dysfunction between sepsis and its preceding risk factors (aging and chronic disease), 2018.

[18] Renee Brady, Dennis O. Frank-Ito, Hien T. Tran, Susanne Janum, Kirsten Møller, Susanne Brix, Johnny T. Ottesen, Jesper Mehlsen, and Mette S. Olufsen. Personalized mathematical model predicting endotoxin-induced inflammatory responses in young men, 2016.

[19] Min Huang, Shaoli Cai, and Jingqian Su. The pathogenesis of sepsis and potential therapeutic targets. *International journal of molecular sciences*, 20(21):5376, 2019.

[20] Rico Berner, Jakub Sawicki, Max Thiele, Thomas Löser, and Eckehard Schöll. Critical parameters in dynamic network modeling of sepsis, 2022.

[21] Kristen A. Windoloski, Susanne Janum, Ronan M. G. Berg, and Mette S. Olufsen. Characterization of differences in immune responses during bolus and continuous infusion endotoxin challenges using mathematical modeling, 2023.

[22] Yuqing Wang, Yun Zhao, Rachael Callcut, and Linda Petzold. Integrating physiological time series and clinical notes with transformer for early prediction of sepsis, 2022.

[23] Peter Chang and Arkaprava Roy. Individualized multi-treatment response curves estimation using rbf-net with shared neurons, 2024.

[24] Kevin Ewig, Xiangwen Lin, Tucker Stewart, Katherine Stern, Grant O'Keefe, Ankur Teredesai, and Juhua Hu. Multi-subset approach to early sepsis prediction, 2023.

[25] Colin B. Fogarty, Mark E. Mikkelsen, David F. Gaieski, and Dylan S. Small. Discrete optimization for interpretable study populations and randomization inference in an observational study of severe sepsis mortality, 2015.

[26] Rukmini Kumar, Gilles Clermont, Yoram Vodovotz, and Carson Chow. Dynamics of acute inflammation, 2004.

[27] Jakub Sawicki, Rico Berner, Thomas Löser, and Eckehard Schöll. Modeling tumor disease and sepsis by networks of adaptively coupled phase oscillators, 2021.

[28] Qifan Zhang, Jia Li, Xiaolu Liang, Haorong Xie, Hang Sun, Xinxin Lin, Jie Zhou, Xiangjun He, and Bili Zhu. The preventive effect of chinese herbal preparation xuebijing against hyperactive inflammation after hepato-pancreato-biliary surgery. *Annals of Translational Medicine*, 7(18):481, 2019.

[29] Robert Gauer, Damon Forbes, and Nathan Boyer. Sepsis: diagnosis and management. *American family physician*, 101(7):409–418, 2020.

[30] Zeyu Wang, Huiying Zhao, Peng Ren, Yuxi Zhou, and Ming Sheng. Learning optimal treatment strategies for sepsis using offline reinforcement learning in continuous space, 2022.

[31] Ruiqing Ding, Fangjie Rong, Xiao Han, and Leye Wang. Cross-center early sepsis recognition by medical knowledge guided collaborative learning for data-scarce hospitals, 2023.

[32] Yuwei Liu, Chen Dan, Anubhav Bhatti, Bingjie Shen, Divij Gupta, Suraj Parmar, and San Lee. Interpretable vital sign forecasting with model agnostic attention maps, 2024.

[33] Yuyang Chen, Kaiming Bi, Chih-Hang J. Wu, David Ben-Arieh, and Ashesh Sinha. An improved mathematical model of sepsis: Modeling, bifurcation analysis, and optimal control study for complex nonlinear infectious disease system, 2022.

[34] MohammadAmin Ansari Khoushabar and Parviz Ghafariasl. Advanced meta-ensemble machine learning models for early and accurate sepsis prediction to improve patient outcomes, 2024.

[35] John Whitehead, Yasin Desai, and Thomas Jaki. Estimation of treatment effects following a sequential trial of multiple treatments, 2019.

[36] Maximilian Dietrich, Silvia Seidlitz, Nicholas Schreck, Manuel Wiesenfarth, Patrick Godau, Minu Tizabi, Jan Sellner, Sebastian Marx, Samuel Knödler, Michael M. Allers, Leonardo Ayala, Karsten Schmidt, Thorsten Brenner, Alexander Studier-Fischer, Felix Nickel, Beat P. Müller-Stich, Annette Kopp-Schneider, Markus A. Weigand, and Lena Maier-Hein. Machine learning-based analysis of hyperspectral images for automated sepsis diagnosis, 2021.

[37] Yan Chen, Lijuan Zhou, Jing Wang, Tianhao Gu, and Shuqing Li. Clinical effect of xuebijing combined with thymosinα1 on patients with severe pneumonia complicated with sepsis and its effect on serum inflammatory factors. *Cellular and Molecular Biology*, 67(6):228–235, 2021.

[38] Jordi Rello, Francisco Valenzuela-Sánchez, Maria Ruiz-Rodriguez, and Silvia Moyano. Sepsis: a review of advances in management. *Advances in therapy*, 34:2393–2411, 2017.

[39] Atanaska Dobreva, Renee Brady, Kamila Larripa, Charles Puelz, Jesper Mehlsen, and Mette S. Olufsen. A physiological model of the inflammatory-thermal-pain-cardiovascular interactions during a pathogen challenge, 2019.

[40] Wan-Chung Hu. Sepsis is a syndrome with hyperactivity of th17-like innate immunity and hypoactivity of adaptive immunity, 2013.

[41] SUN Wu, ZHAO Yuwei, LIAO Liang, ZHAO Zhonghui, CHEN Shiqi, YAN Xiaoling, WANG Xueyao, CHAO Guojun, and ZHOU Jian. Effectiveness and safety of xuebijing injection for patients with coronavirus disease 2019: A systematic review and meta-analysis. *Journal of Traditional Chinese Medicine*, 43(4):631, 2023.

[42] Bruno Petrungaro, Neville K. Kitson, and Anthony C. Constantinou. Investigating potential causes of sepsis with bayesian network structure learning, 2025.

[43] Andrew Rhodes, Laura E Evans, Waleed Alhazzani, Mitchell M Levy, Massimo Antonelli, Ricard Ferrer, Anand Kumar, Jonathan E Sevransky, Charles L Sprung, Mark E Nunnally, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. *Intensive care medicine*, 43:304–377, 2017.

[44] Chia-Hsuan Chang, Xiaoyang Wang, and Christopher C. Yang. Explainable ai for fair sepsis mortality predictive model, 2024.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.

AI-generated, for reference only.